載入...
Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells
Inactivating mutations in ARID1A are found in a broad spectrum of cancer types, with the highest frequency in gynecologic cancers. However, therapeutic strategies targeting ARID1A-mutant cancer cells remain limited. In this study, we aimed to identify drugs sensitivities in ARID1A-mutant cancer cell...
Na minha lista:
發表在: | Oncotarget |
---|---|
Main Authors: | , , , , , , , , |
格式: | Artigo |
語言: | Inglês |
出版: |
Impact Journals LLC
2016
|
主題: | |
在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5302963/ https://ncbi.nlm.nih.gov/pubmed/27486766 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10921 |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|